Patents | Published:


Evolution of CAR T-cell immunotherapy in terms of patenting activity

Nature Biotechnologyvolume 37pages370375 (2019) | Download Citation


An analysis of published patent applications in chimeric antigen receptor (CAR) T-cell immunotherapy allows insight into the development of this emerging technology.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

  • 09 April 2019

    In the version of this article initially published online, the abstract read “dedvelopment” instead of “development” as a result of a publisher error. The error has been corrected in the print, PDF and HTML versions of this article.


  1. 1.

    Kolata, G. New gene-therapy treatments will carry whopping price tags. The New York Times (11 September 2017).

  2. 2.

    Grady, D. Companies rush to develop ‘utterly transformative’ gene therapies. The New York Times (23 July 2017).

  3. 3.

    Sadelain, M. & Rivière, I. CAR T cells in cancer therapy (poster). Nat. Rev. Drug Disc. (December 2017).

  4. 4.

    Golstein, P. & Griffiths, G. M. Nat. Rev. Immunol. 18, 527–535 (2018).

  5. 5.

    Mullard, A. Nat. Rev. Drug Discov. 14, 301 (2015).

  6. 6.

    Morrison, C. Nat. Biotechnol. 33, 571–572 (2015).

  7. 7.

    Dolgin, E. Nat. Biotechnol. 35, 891–892 (2017).

  8. 8.

    Trippe, A. Guidelines for Preparing Patent Landscape Reports (World Intellectual Property Organization, 2015).

  9. 9.

    Zuniga, P. et al. OECD Patent Statistics Manual (OECD, 2009).

  10. 10.

    European IPR Helpdesk. E-IPR fact sheet: automatic patent analysis. (2013).

  11. 11.

    Jürgens, B. & Herrero-Solana, V. J. Intell. Stud. Bus. 7, 17–26 (2017).

  12. 12.

    Dara, A. & Sangamwar, A. T. PLoS One 9, e103847 (2014).

  13. 13.

    Pan, C. L. & Chen, F. C. Hum. Vaccin. Immunother. 13, 2583–2593 (2017).

  14. 14.

    Anaya, M., Perez-Santos, M. & Muñoz-Rojas, J. Intl. J. Cancer Biol. Clin. Oncol. 1, 14–18 (2017).

  15. 15.

    Anonymous. Nat. Biotechnol. 35, 215 (2017).

  16. 16.

    Bouchie, A., Allison, M., Webb, S. & DeFrancesco, L. Nat. Biotechnol. 32, 229–238 (2014).

  17. 17.

    Bouchie, A. & DeFrancesco, L. Nat. Biotechnol. 33, 247–255 (2015).

  18. 18.

    Morrison, C. Nat. Biotechnol. 36, 131–136 (2018).

  19. 19.

    Yeager, A.J. CAR-T in the courts. Genetic Engineering News (11 September 2017).

Download references


This article is based on a study that was commissioned by the European Patent Office with the aim of demonstrating to readers outside the disciplines of patent analysis and CAR T-cell immunotherapy how patent information can be used to gain insight and competitive advantages about a specific technological field. The authors thank F. Aslund, P. Bumb and D. Manu from the European Patent Office for their support in the classification identification process and assistance for fine-tuning the search strategy. The opinions expressed in this article are those of the authors and not necessarily those of their employers.

Author information

Author notes

  1. These authors contributed equally: Björn Jürgens, Nigel S. Clarke.


  1. CITPIA PATLIB Center, Agency for Innovation and Development of Andalusia, Seville, Spain

    • Björn Jürgens
  2. European Patent Office, Vienna, Austria

    • Nigel S. Clarke


  1. Search for Björn Jürgens in:

  2. Search for Nigel S. Clarke in:

Competing interests

The authors declare no competing interests.

Corresponding author

Correspondence to Nigel S. Clarke.

Supplementary Information

  1. Supplementary Information

    Supplementary Methods

About this article

Publication history


Issue Date